- Published: December 2010
R&D Trends: Benign Prostatic Hyperplasia – Small Pipeline which Lacks Promise
- Published: April 2012
- Region: World
- 31 Pages
Review of key trends in the development of new benign prostatic hyperplasia drugs across the seven major markets. Includes analyses of clinical trial design, target product profile, innovative early-stage projects, and future treatment developments.
New therapies have entered the benign prostatic hyperplasia (BPH) drug market since Datamonitor reviewed the market in 2009, including Rapaflo (silodosin; Recordati) and Duodart/Jalyn (dutasteride and tamsulosin; GlaxoSmithKline). Meanwhile, the failure of AEterna Zentaris's cetrorelix to meet Phase III efficacy endpoints signals the end of gonadotropin-releasing hormones being approved for BPH.
- Understand key dynamics in the R&D pipeline for new BPH therapies.
- Support R&D decision-making by understanding the competitive dynamics of the pipeline.
- Benchmark pipeline candidates using the target product profile identified by Datamonitor.
- Access Datamonitor's prediction of how the treatment landscape may change in the next 20 years.
- Datamonitor identified 18 drugs in clinical development for BPH, with orally delivered candidates accounting for 43% of the R&D pipeline. Still, key opinion leaders believe that the pipeline shows little promise and remain pessimistic about the future treatment of BPH.
- Datamonitor regards Flomax (tamsulosin; Astellas/Boehringer Ingelheim) as the gold standard for symptom relief, while Avodart (dutasteride; GlaxoSmithKline) is the gold-standard disease-modifying therapy. However, Avodart's drawbacks include a minimal symptomatic effect, lengthy time to induce therapeutic action, and sexual dysfunction.
- Opinion leaders foresee an increase in the use of surgical management over the next decade. This is in spite of the risks and costs associated with surgery and will be driven by technological advances and the improved outcomes that surgery offers in comparison to drug treatments.
Reasons to Purchase
- What are the key trends in the benign prostatic hyperplasia pipeline?
- What is the ideal target product profile for a new drug treatment for benign prostatic hyperplasia?
- How will the management of benign prostatic hyperplasia evolve over the next 2 decades?
- What is the clinical gold standard and how do new candidates have to compare to this to successfully penetrate the BPH market? SHOW LESS READ MORE >
- Strategic scoping and focus
- Datamonitor key findings
- Related reports
CLINICAL PIPELINE OVERVIEW
- The benign prostatic hyperplasia pipeline remains lackluster
- Mechanism of action Despite failures, disease-modifying products continue to account for the largest single proportion of the pipeline
- Symptomatic relief agents
- Disease-modifying agents
- Late-stage development compounds recently discontinued
TARGET PRODUCT PROFILE Symptomatic relief - tamsulosin Flomax (tamsulosin; Astellas/Boehringer Ingelheim)
- Disease-modifying - Avodart (dutasteride; GlaxoSmithKline) Key clinical trials
- Target product profile versus current level of attainment
CLINICAL TRIAL DESIGN IN BENIGN PROSTATIC HYPERPLASIA
- Clinical trials Recruitment criteria
- Primary endpoints
- Secondary endpoints
INNOVATIVE EARLY-STAGE APPROACHES LS11 (talaporfin sodium)
- Mechanism of action - a light-activated drug to provide localized drug action
- Clinical studies have begun
THE FUTURE OF TREATMENT IN BENIGN PROSTATIC HYPERPLASIA
- Surgical management will increase
- Greater use of molecular profiling
- Dendreon Corporation
- GlaxoSmithKline Plc
- Hutchison 3G UK Limited
- Nymox Pharmaceutical Corporation
|Electronic (PDF)||The report will be emailed to you. The report is sent in PDF format.||This is a single user license, allowing one specific user access to the product.|
|Enterprisewide||The report will be emailed to you. The report is sent in PDF format.||This is an enterprise license, allowing all employees within your organisation access to the product.|